

## Serovars and antimicrobial resistance of non-typhoidal *Salmonella* from human patients in Shanghai, China, 2006–2010

J. ZHANG<sup>1</sup>\*, H. JIN<sup>2</sup>, J. HU<sup>2</sup>, Z. YUAN<sup>2</sup>, W. SHI<sup>3</sup>, L. RAN<sup>4</sup>, S. ZHAO<sup>5</sup>,  
X. YANG<sup>1</sup>, J. MENG<sup>6</sup> AND X. XU<sup>2</sup>\*

<sup>1</sup> Department of Food Science & Technology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China

<sup>2</sup> Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China

<sup>3</sup> Shanghai Municipal Ke-Ma-Jia Technology Center for Microbiology, Shanghai, China

<sup>4</sup> China Center for Disease Control and Prevention, Beijing, China

<sup>5</sup> Division of Animal and Food Microbiology, Office of Research, Center for Veterinary Medicine, US Food and Drug Administration, Laurel, MD, USA

<sup>6</sup> Department of Food Science and Nutrition, University of Maryland, College Park, MD, USA

Received 8 April 2013; Final revision 20 June 2013; Accepted 20 June 2013;  
first published online 10 July 2013

### SUMMARY

We conducted a retrospective study on non-typhoidal *Salmonella* isolates from patients with diarrhoea in Shanghai, China, 2006–2010. A total of 1484 isolates of 70 *Salmonella* serovars were recovered from about 18000 stool specimens. Serovars Enteritidis and Typhimurium were the most prevalent with isolation rates of 27·6% and 25·5%, respectively. The majority (1151, 77·6%) of the isolates were resistant to at least one antimicrobial, and 598 (40·3%) to more than three antimicrobials. Approximately half (50·9%) of the isolates were resistant to nalidixic acid and other resistance rates were sulfisoxazole (47·9%), streptomycin (37·6%), ampicillin (31·3%) and tetracycline (30·5%). Co-resistance to fluoroquinolones and the third- and fourth-generation cephalosporins was also identified.

**Key words:** Antimicrobial resistance, *Salmonella*, serovars.

### INTRODUCTION

Non-typhoidal *Salmonella* infection is a serious threat to global public health, causing an estimated 93·8 million illnesses and 155 000 deaths worldwide every year [1, 2]. Most (95%) *Salmonella* infections in humans are attributed to ingestion of contaminated foods [3]. While usually self-limiting in most individuals, salmonellosis may require antimicrobial drug treatment in infants, the elderly, and immunocompromised

individuals. However, antimicrobial resistance has become increasingly common among *Salmonella*. Because antimicrobial resistance varies widely between and within countries, surveillance is essential to provide data on the magnitude and trends in resistance and to monitor the effect of interventions [4]. The emergence and spread of antimicrobial-resistant *Salmonella*, particularly multidrug-resistant (MDR) strains, has been reported in many countries [5–9] and is increasingly of major concern as these strains reduce the therapeutic options in cases of invasive infections and have serious public health implications. Unfortunately, the spectrum of antimicrobial resistance in *Salmonella* is also increasing and extends to resistance to fluoroquinolones (ciprofloxacin) and third- and fourth-generation

\* Author for correspondence: Dr J. Zhang, Department of Food Science and Technology, Shanghai Jiao Tong University, Shanghai 200240, China.  
(Email: junfeng-v@163.com) [J. Zhang]  
(Email: xbxu@scdc.sh.cn) [X. Xu]

cephalosporins (ceftriaxone). As these drugs are the primary choice for the treatment of invasive salmonellosis in humans, the appearance of resistance to such antimicrobials is of particular concern.

Despite an estimated high number of salmonellosis cases in many parts of the world, there is a lack of data on the infection and antimicrobial-resistant *Salmonella* in China. The Shanghai Center for Disease Control and Prevention (SCDC), participating in the World Health Organization Global Foodborne Infections Network (WHO-GFN) since 2005, has performed isolation, identification and characterization of foodborne pathogens recovered from patients. The present report provides data on serovars, and antimicrobial resistance of *Salmonella* isolated from patients with diarrhoea in Shanghai from 2006 to 2010.

## MATERIALS AND METHODS

### Specimen collection

This study was conducted at 24 sentinel hospitals and eight regional SCDC diagnostic laboratories located in five districts of Shanghai (Children's Hospital of Shanghai, and Children's Hospital of Fudan University were added to this project in 2010). Physicians were asked to collect stool samples from patients who presented with  $\geq 3$  loose stools within 1 day and had other symptoms such as fever, vomiting, or abdominal pain [10]. Demographic and clinical information for each case, including age, gender, symptoms, date of illness onset, and date of specimen collection, was collected and electronically transmitted to SCDC.

### Bacteriological examination

The clinical laboratories used a standardized procedure to isolate *Salmonella* from stools [11]. Stool specimens were enriched in tetrathionate Brilliant-Green broth or selenite broth for 6–8 h at 37 °C, followed by subcultivation on Hektoen Enteric agar, *Salmonella-Shigella* agar, or CHROMagar *Salmonella* agar (Becton Dickinson, USA). The plates were incubated at 37 °C for 18–24 h and presumptive colonies were further tested using triple-sugar-iron agar, motility indole urea agar, L-lysine decarboxylase, and L-galactosidase (*o*-nitrophenyl-L-D-galactopyranoside; ONPG). Isolates were confirmed as *Salmonella* using API 20E test strips (bioMérieux, France). O and H antigens were characterized by slide agglutination with commercial

antiserum (S&A Reagents Laboratory, Thailand), and serovars were assigned according to the Kauffmann–White scheme [12].

### Antimicrobial susceptibility testing

Isolates were tested for susceptibility to 16 antimicrobials using the Kirby–Bauer disk diffusion method [13]. The antimicrobials were ampicillin (10 µg), cefotaxime (30 µg), nalidixic acid (30 µg), ciprofloxacin (5 µg), ceftazidime (30 µg), gentamicin (10 µg), tetracycline (30 µg), chloramphenicol (30 µg), ceftiofur (30 µg), amoxicillin/clavulanate acid (30 µg), trimethoprim/sulfamethoxazole (1·25/23·75 µg), ofloxacin (5 µg), cefepime (5 µg), trimethoprim (5 µg), sulfisoxazole (300 µg), and streptomycin (10 µg). *Escherichia coli* ATCC 25922 and ATCC 35218 were used as quality control organisms. Results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines [14].

### Statistical analysis

A  $\chi^2$  or Fisher's exact test was used for data analysis using SAS v. 9.2 (SAS Institute Inc., USA). A *P* value of <0·05 was considered statistically significant.

## RESULTS

Between January 2006 and December 2010, a total of 18 000 stool specimens were cultured from patients with diarrhoea in Shanghai, resulting in 1484 (8·2%) *Salmonella* isolates. The number of isolates per annum ranged from 166 to 679 over the sample period (Table 1). Seventy serovars were identified with 10 serovars accounting for nearly 80% (1177) of the isolates, chief of which were Enteritidis (410, 27·6%), Typhimurium (379, 25·5%), Senftenberg (90, 6·1%), Thompson (52, 3·5%), and Agona (45, 3·0%). The other 60 serovars were distributed among the remaining 307 isolates (Table 1).

The age range of patients spanned from 2 days to 91 years. Of 1204 isolates from 2006 to 2010 (except those from Shanghai Children's Hospital and Children's Hospital of Fudan University), 76·4% were from adults aged 18–60 years. However, most isolates (79·6%) from Shanghai Children's Hospital and Children's Hospital of Fudan University in 2010 were recovered from children aged <4 years (Table 2). The male/female ratio of positive isolation was 1·1:1.

Table 1. Top 10 serovars of *Salmonella* isolates from humans (2006–2010) in Shanghai, China

| Serotype    | No. (%) of isolates |              |              |              |              |                |
|-------------|---------------------|--------------|--------------|--------------|--------------|----------------|
|             | 2006 (n=196)        | 2007 (n=166) | 2008 (n=207) | 2009 (n=236) | 2010 (n=679) | Total (n=1484) |
| Enteritidis | 44                  | 40           | 73           | 62           | 191          | 410 (27.6)     |
| Typhimurium | 35                  | 30           | 50           | 68           | 196          | 379 (25.5)     |
| Senftenberg | 34                  | 5            | 14           | 17           | 20           | 90 (6.1)       |
| Thompson    | 2                   | 22           | 3            | 11           | 14           | 52 (3.5)       |
| Agona       | 6                   | 7            | 4            | 3            | 25           | 45 (3.0)       |
| London      | 1                   | 0            | 23           | 2            | 18           | 44 (3.0)       |
| Aberdeen    | 10                  | 13           | 3            | 7            | 10           | 43 (2.9)       |
| Infantis    | 6                   | 15           | 1            | 9            | 10           | 41 (2.8)       |
| Derby       | 9                   | 3            | 2            | 8            | 17           | 39 (2.6)       |
| Meleagridis | 1                   | 2            | 2            | 4            | 25           | 34 (2.3)       |
| Others      | 48                  | 29           | 32           | 45           | 153          | 307 (20.7)     |

Table 2. Distribution of human *Salmonella* isolates by gender and age (2006–2010), Shanghai, China

| Year  | No. (%)    |            |           |             |      |       |     |         |
|-------|------------|------------|-----------|-------------|------|-------|-----|---------|
|       | Gender     |            |           | Age (years) |      |       |     |         |
|       | Males      | Females    | Unknown   | ≤4          | 5–17 | 18–60 | >60 | Unknown |
| 2006  | 85 (43.4)  | 111 (56.6) | 0         | 3           | 12   | 158   | 23  | 0       |
| 2007  | 85 (51.2)  | 81 (48.8)  | 0         | 1           | 5    | 140   | 20  | 0       |
| 2008  | 112 (54.1) | 87 (42)    | 8 (3.9)   | 0           | 9    | 164   | 26  | 8       |
| 2009  | 122 (51.7) | 105 (44.5) | 9 (3.8)   | 7           | 10   | 179   | 31  | 9       |
| 2010* | 199 (49.9) | 187 (46.9) | 13 (3.3)  | 33          | 12   | 279   | 66  | 9       |
| 2010† | 146 (52.1) | 98 (35)    | 36 (12.9) | 223         | 18   | 0     | 0   | 39      |
| Total | 749 (50.5) | 669 (45.1) | 66 (4.4)  | 267         | 66   | 920   | 166 | 65      |

\* *Salmonella* data from Shanghai excluding those from Children's Hospital of Shanghai, and Children's Hospital of Fudan University in 2010.

† *Salmonella* data from Children's Hospital of Shanghai, and Children's Hospital of Fudan University in 2010.

Most isolates (77.6%) were resistant to one or more antimicrobials and 50.9% were resistant to nalidixic acid, followed by sulfisoxazole (47.9%), streptomycin (37.6%), ampicillin (31.3%), tetracycline (30.5%) (Table 3). Resistance was also observed, but to a lesser extent, to ceftiofur (6.4%), amoxicillin/clavulanate acid (4.7%), ceftazidime (3.8%), cefotaxime (3.6%), ciprofloxacin (2.8%), cefepime (2.1%), and ofloxacin (1.4%). Of the top three serovars (Enteritidis, Typhimurium, Senftenberg), Typhimurium exhibited the highest percentages of resistance to each of these drugs (2.4–6.6%) (Fig. 1), whereas Senftenberg displayed resistance only to ceftazidime (3%).

The emergence or increase in resistance to certain antimicrobials during the study period is noteworthy (Table 3). All isolates from 2006 were susceptible to ceftiofur, cefepime, ofloxacin, and ciprofloxacin but by

2009, resistance rates of 17% to ceftiofur, 1.7% to cefepime, 5.1% to ofloxacin, and 6.8% to ciprofloxacin were found. Significant increase in resistance to other antimicrobials was also recorded for isolates from 2006 to 2009: tetracycline (17.3–32.1%,  $P < 0.01$ ), ampicillin (12.3–33%,  $P < 0.01$ ), amoxicillin/clavulanate acid (0.5–6.8%,  $P < 0.01$ ), nalidixic acid (37.2–54.7%  $P < 0.01$ ), trimethoprim (8.2–20.3%,  $P < 0.01$ ), sulfamethoxazole/trimethoprim (8.7–18.2%,  $P < 0.01$ ), gentamicin (5.1–17%,  $P < 0.01$ ), and streptomycin (16.8–45.8%,  $P < 0.01$ ). Interestingly, most antimicrobial resistance rates (except ciprofloxacin and ofloxacin) of strains isolated from Shanghai Children's Hospital and Children's Hospital of Fudan University were higher than those from other hospitals in 2010 (Table 3), indicating difference in antimicrobial treatment between infections from children and adults.

Table 3. Antimicrobial resistance of *Salmonella* isolates from humans in Shanghai, China, 2006–2010

| Antimicrobial                 | % of resistance   |                   |                   |                   |                    |                    | Total<br>(n = 1484) |
|-------------------------------|-------------------|-------------------|-------------------|-------------------|--------------------|--------------------|---------------------|
|                               | 2006<br>(n = 196) | 2007<br>(n = 166) | 2008<br>(n = 207) | 2009<br>(n = 236) | 2010*<br>(n = 399) | 2010†<br>(n = 280) |                     |
| Tetracycline                  | 17.3              | 21.1              | 20.3              | 30                | 32.1               | 51.4               | 30.5                |
| Ampicillin                    | 12.3              | 24.1              | 25.1              | 33                | 31.8               | 56.1               | 31.3                |
| Amoxicillin/clavulanate acid  | 0.5               | 4.8               | 1                 | 6.8               | 4.5                | 8.9                | 4.7                 |
| Ceftiofur                     | 0                 | 0                 | 1.9               | 17                | 3                  | 13.9               | 6.4                 |
| Ceftazidime                   | 2.6               | 0                 | 1                 | 3.8               | 2                  | 11.4               | 3.8                 |
| Cefepime                      | 0                 | 0                 | 0                 | 1.7               | 0.8                | 8.6                | 2.1                 |
| Cefotaxime                    | 0.5               | 0                 | 1.4               | 3.8               | 1.5                | 12.1               | 3.6                 |
| Nalidixic acid                | 37.2              | 39.2              | 56.5              | 54.7              | 49.1               | 62.5               | 50.9                |
| Ofloxacin                     | 0                 | 1.2               | 1                 | 5.1               | 0.8                | 0.7                | 1.4                 |
| Ciprofloxacin                 | 0                 | 0.6               | 1.9               | 6.8               | 3.3                | 2.9                | 2.8                 |
| Trimethoprim                  | 8.2               | 10.8              | 9.7               | 20.3              | 22.3               | 36.4               | 19.7                |
| Sulfamethoxazole/trimethoprim | 8.7               | 10.2              | 8.7               | 18.2              | 23.3               | 37.5               | 19.7                |
| Sulfisoxazole                 | 59.2              | 40.4              | 41.5              | 46.2              | 42.6               | 58.2               | 47.9                |
| Chloramphenicol               | 10.8              | 12.7              | 5.3               | 16.1              | 15                 | 29.1               | 15.7                |
| Gentamicin                    | 5.1               | 4.8               | 7.7               | 17                | 17                 | 29.6               | 15.2                |
| Streptomycin                  | 16.8              | 28.9              | 25.6              | 45.8              | 42.9               | 51.8               | 37.6                |

\* Antimicrobial resistance data of *Salmonella* from Shanghai excluding those from Children's Hospital of Shanghai, and Children's Hospital of Fudan University in 2010.

† Antimicrobial resistance data of *Salmonella* from Children's Hospital of Shanghai, and Children's Hospital of Fudan University in 2010.

For example, ciprofloxacin is generally not used for young children.


Importantly, a large proportion of the resistant isolates (40.3%) were resistant to  $\geq 3$  antimicrobial agents and these were predominantly the serovars Enteritidis (34.4%) and Typhimurium (33.6%), with the most common resistance phenotypes being nalidixic acid, sulfisoxazole and streptomycin. Thirty-eight isolates were resistant to  $>10$  antimicrobials tested and four isolates to 15 antimicrobials, including sulfonamides, fluoroquinolones, tetracyclines, aminoglycosides and  $\beta$ -lactamases. Eight isolates (three Enteritidis and five Typhimurium) were co-resistant to fluoroquinolones and third- and fourth-generation cephalosporins in addition to 5–10 other antimicrobials.

## DISCUSSION

This study provided comprehensive data on serovars and antimicrobial susceptibility of non-typhoidal *Salmonella* from diarrhoea patients in Shanghai from 2006 to 2010. Enteritidis and Typhimurium were the most common serovars as reported in other parts of the world [15, 16], although our other top ranking serovars differed from some countries. For example,

Newport, Javiana, I4, [5], 12:i:-, and Heidelberg were among the top 10 serovars reported from the USA and Canada. On the other hand, Senftenberg, Thompson, Agona, London, Aberdeen, Derby and Meleagridis were among the top 10 serovars in this series with Senftenberg the third most frequently isolated serovar in Shanghai. Interestingly, this serovar has mostly been described as an uncommon human pathogen in the past but was one of the 10 most prevalent serovars from animal farms in England and Wales [17], and a predominant serovar from marine environments and seafood, especially in temperate and tropical zones [18].

The worldwide emergence of resistance to antimicrobials in bacterial pathogens is an important public health problem [5, 8, 19] and an increased number of *Salmonella* isolates have become multidrug resistant in many developing and developed countries [20]. Resistance to several clinically important drugs including quinolones/fluoroquinolones and the third- and fourth-generation cephalosporins is particularly troublesome. Studies have shown that *Salmonella* resistant to nalidixic acid also displayed decreased susceptibility to ciprofloxacin, and that infections with ciprofloxacin-resistant *Salmonella* were associated with increased mortality [21]. Nalidixic acid resistance



**Fig. 1.** Resistance to fluoroquinolones, and to third- and fourth-generation cephalosporins in *Salmonella* serovars Enteritidis, Typhimurium and Senftenberg from humans in Shanghai, China.

in non-typhoid *Salmonella* was reported in many countries in the mid-1990s [22–24] and accounted for less than 18% of isolates in Europe in 2000 [9]. More recently nalidixic acid resistance rates of *Salmonella* in India and Taiwan (Typhimurium) were reported to be 20% and 21.6%, respectively [25, 26], but this contrasts with 2% for all *Salmonella* and 0.2% which were ciprofloxacin resistant in the USA in 2010, and 3.8% of *S. Typhimurium* in Korea reported in 2004; none of which were ciprofloxacin resistant [27, 28]. Our finding that nalidixic acid resistance was the most common resistance phenotype (50.9%) in clinical isolates of *Salmonella* in Shanghai, and that 2.8% were also resistant to ciprofloxacin is therefore noteworthy although similar resistance rates for these drugs have been reported in other regions of China, indicating a national trend [29, 30]. The emergence of ciprofloxacin resistance in *Salmonella* is of public health significance as it indicates possible over-prescription in humans and misuse in animals. This may lead to potential failure in the treatment of patients infected with fluoroquinolone-resistant strains and therefore physicians in Shanghai and China in general need to consider determining the antibiogram of all isolates to ensure effective treatment of patients with *Salmonella* infection.

Resistance to sulphonamides has been described in the literature to varying degrees in different countries. In the USA, about 28% *S. Typhimurium* were resistant to sulfisoxazole [27], whereas 97% and 43% of *S. Typhimurium* were resistant to the drug in Japan and Denmark, respectively [26, 31]. A relatively high

level of resistance to sulfisoxazole (47.9%) was also observed in this study.

Cephalosporins are among the most diverse classes of antimicrobials, and are grouped into ‘generations’ by their antimicrobial properties. Each generation has a broader spectrum of activity than a previous one. Resistance to these drugs has been reported in several countries, albeit at a relatively low rate [26, 27]. Unfortunately, the present study revealed the emergence of co-resistance to fluoroquinolones (ciprofloxacin and ofloxacin), and third-generation (ceftazidime and cefotaxime) and fourth-generation (cefepime) cephalosporins in Enteritidis and Typhimurium isolates. These drugs are among the most widely used worldwide, and are considered critically important in human medicine according to WHO criteria [32] as they are reserved for use in the hospital setting to treat patients with serious and life-threatening infections. The emergence and increased resistance rates to these drugs is therefore particularly alarming. Our findings support the need of continuing active surveillance of antimicrobial resistance in *Salmonella* and other bacterial pathogens as it is essential to the safe and effective use of antimicrobial drugs for humans thereby protecting public health.

#### ACKNOWLEDGEMENTS

This work was funded in part by Mega-projects of Science and Technology Research of China (No. 2012ZX10004215–003), the Subproject 6 of the Sino-US EID (Emerging Infectious Diseases)

Cooperation Project and the China Postdoctoral Science Foundation funded project (Nos. 2012T50419, 2011M500781)

## DECLARATION OF INTEREST

None.

## REFERENCES

1. **Tauxe RV.** Emerging foodborne diseases: an evolving public health challenge. *Emerging Infectious Diseases* 1997; **3**: 425–434.
2. **Majowicz SE, et al.** The global burden of nontyphoidal *Salmonella* gastroenteritis. *Clinical Infectious Diseases* 2010; **50**: 882–889.
3. **Gomez TM, et al.** Foodborne salmonellosis. *World Health Statistics Quarterly* 1997; **50**: 81–89.
4. **World Health Organization (WHO).** WHO global strategy for containment of antimicrobial resistance. WHO, Switzerland, 2001.
5. **Cailhol J, et al.** Trends in antimicrobial resistance phenotypes in non-typhoid *Salmonella* from human and poultry origins in France. *Epidemiology and Infection* 2006; **134**: 171–178.
6. **Lauderdale TL, et al.** Multidrug resistance among different serotypes of clinical *Salmonella* isolates in Taiwan. *Diagnostic Microbiology Infectious Disease* 2006; **55**: 149–155.
7. **Van Duijkeren E, et al.** Antimicrobial susceptibilities of *Salmonella* strains isolated from humans, cattle, pigs, and chickens in the Netherlands from 1984 to 2001. *Journal of Clinical Microbiology* 2003; **41**: 3574–3578.
8. **Xia S, et al.** Molecular characterization and antimicrobial susceptibility of *Salmonella* isolates from infections in humans in Henan Province, China. *Journal of Clinical Microbiology* 2009; **47**: 401–409.
9. **Threlfall EJ, et al.** Antimicrobial drug resistance in isolates of *Salmonella* enterica from cases of salmonellosis in humans in Europe in 2000: results of international multi-centre surveillance. *Eurosurveillance* 2003; **8**: 41–45.
10. **Centers for Disease Control and Prevention (CDC).** Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. *Morbidity and Mortality Weekly Report* 2004; **53**: 1–33.
11. **World Health Organization (WHO).** Isolation of *Salmonella* and *Shigella* from faecal specimens. WHO Global Foodborne Infections Network, 2010 (<http://www.who.int/gfn/en/>). Accessed 15 December 2011.
12. **World Health Organization (WHO).** Collaborating Centre for Reference and Research on *Salmonella*. Antigenic formulae of the *Salmonella* serovars. Paris: Pasteur Institute, 2001.
13. **Clinical and Laboratory Standards Institute.** Performance standards for antimicrobial disk susceptibility tests. M02-A10. Villanova, PA, USA: CLSI, 2009.
14. **Clinical and Laboratory Standards Institute.** Performance standards for antimicrobial susceptibility testing: 20th informational supplement. M100-S20. Villanova, PA, USA: CLSI, 2010.
15. **Herikstad H, et al.** *Salmonella* surveillance: a global survey of public health serotyping. *Epidemiology and Infection* 2002; **129**: 1–8.
16. **Galanis E, et al.** Web-based surveillance and global *Salmonella* distribution, 2000–2002. *Emerging Infectious Diseases* 2006; **12**: 381–388.
17. **Liebana E, et al.** Molecular typing of *Salmonella* serotypes prevalent in animals in England: assessment of methodology. *Journal of Clinical Microbiology* 2001; **39**: 3609–3616.
18. **Martinez-Urtaza J, et al.** Detection of *Salmonella* Senftenberg associated with high saline environments in mussel processing facilities. *Journal of Food Protection* 2004; **67**: 256–263.
19. **Cui S, et al.** Ciprofloxacin-resistant *Salmonella* enterica serotype Typhimurium, China. *Emerging Infectious Diseases* 2008; **14**: 493–5.
20. **Ashtiani MT, et al.** Trends in antimicrobial resistance of fecal *Shigella* and *Salmonella* isolates in Tehran, Iran. *Indian Journal of Pathology and Microbiology* 2009; **52**: 52–55.
21. **Travers K, Barza M.** Morbidity of infections caused by antimicrobial-resistant bacteria. *Clinical Infectious Diseases* 2002; **34**: S131–S134.
22. **Breuil J, et al.** Antibiotic resistance in *Salmonellae* isolated from humans and animals in France: comparative data from 1994 and 1997. *Journal of Antimicrobial Chemotherapy* 2000; **46**: 965–971.
23. **Prats G, et al.** Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985–1987 and 1995–1998 in Barcelona. *Antimicrobial Agents and Chemotherapy* 2000; **44**: 1140–1145.
24. **Threlfall EJ, et al.** Resistance to ciprofloxacin in non-typhoidal *Salmonellas* from humans in England and Wales—the current situation. *Clinical Microbiology and Infection* 1999; **5**: 130–134.
25. **Singh S, et al.** Antibiotic resistance pattern among the *Salmonella* isolated from human, animal and meat in India. *Tropical Animal Health and Production* 2012; **44**: 665–674.
26. **Torpdahl M, et al.** Human isolates of *Salmonella* enterica serovar Typhimurium from Taiwan displayed significantly higher levels of antimicrobial resistance than those from Denmark. *International Journal of Food Microbiology* 2013; **161**: 69–75.
27. **Centers for Disease Control and Prevention (CDC).** National Antimicrobial Resistance Monitoring System for Enteric Bacteria. (NARMS): Human isolates, final report, 2010 (<http://www.cdc.gov/narms/pdf/2010-annual-report-narms.pdf>), 2010.
28. **Yoo S, et al.** Epidemiology of *Salmonella* enterica serotype typhi infections in Korea for recent 9 years: trends of antimicrobial resistance. *Journal of Korean Medical Science* 2004; **19**: 15–20.
29. **Deng X, et al.** Laboratory-based surveillance of non-typhoidal *Salmonella* infections in Guangdong

- Province, China. *Foodborne Pathogens and Disease* 2012; **9**: 305–312.
30. **Ran L, et al.** Laboratory-based surveillance of non-typhoidal *Salmonella* infections in China. *Foodborne Pathogens and Disease* 2011; **8**: 921–927.
31. **Shahada F, et al.** Antimicrobial susceptibility phenotypes, resistance determinants and DNA fingerprints of *Salmonella* enterica serotype Typhimurium isolated from bovine in Southern Japan. *International Journal of Antimicrobial Agents* 2007; **30**: 150–156.
32. **Paterson DL, Bonomo RA.** Extended-spectrum beta-lactamases: a clinical update. *Clinical Microbiology Reviews* 2005; **18**: 657–686.